{
    "clinical_study": {
        "@rank": "119541", 
        "arm_group": {
            "arm_group_label": "ILYANG Inactivated split influenza vaccine", 
            "arm_group_type": "Experimental", 
            "description": "IL-YANG FLU Vaccine Vial INJ 0.5mL by intramuscular injection"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG\n      Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Vial INJ.) administered as a single\n      intramuscular injection"
        }, 
        "brief_title": "Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "This was an open-label study. Subjects providing voluntary written informed consent\n      underwent protocol-specific assessments and tests within 4 weeks prior to administration of\n      the study vaccine, and those who met all of the inclusion/exclusion criteria and were\n      considered eligible were sequentially enrolled in the study.\n\n      Subjects enrolled in the study received 0.5ml of the study vaccine as an intramuscular\n      injection in the deltoid muscle, and returned to the clinic every day for the first 3 days.\n      On Day 14 post-vaccination, subjects underwent the safety assessments. On Day 28\n      post-vaccination, subjects returned for safety and immunogenicity assessments."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males between 20 and 55 years of age at screening\n\n          -  Body weight of \u2265 55kg and within \u00b120% of ideal body weight (ideal body weight  =\n             (height cm - 100) X 0.9) at screening\n\n          -  Subjects with no congenital or chronic disease who were considered suitable for the\n             study after screening assessments (investigator's opinion, medical history, physical\n             examination, laboratory test, chest X-ray, and ECG) conducted within 28 days prior to\n             vaccination\n\n          -  Subjects who were given, and fully understood, the information about the study, made\n             a voluntary decision, and provided written informed consent, to participate in the\n             study and comply with all applicable study requirements\n\n        Exclusion Criteria:\n\n          -  Subjects with pre-vaccination HI antibody titer \u2265 1:40\n\n          -  Subjects who have known or suspected infection with HAV, HBV, HCV, HIV or VDRL (via\n             ELISA screening or medical history taking)\n\n          -  Subjects who have concurrent or a past history of immune deficiency disease\n\n          -  Subject who had participated in blood donation within 1 week prior to vaccination, or\n             are planning to participate in blood donation from Day 1 until Month 7\n             post-vaccination\n\n          -  Subject with a history of Guillain-Barre syndrome\n\n          -  Subject with hemophilia, thrombocytopenia or being treated with an anticoagulant, who\n             are at increased risk of serious bleeding during intramuscular injection\n\n          -  Subjects who have concurrent or a past history of, malignant tumor of internal organ\n             or blood vessels or skin metastasis\n\n          -  Subjects with known allergy to a drug, food or latex, who had a history of\n             anaphylaxis\n\n          -  Subjects who had an acute fever with body temperature > 38.0 C\u00ba within 72 hours prior\n             to administration of the study vaccine or symptoms of suspected acute disease within\n             14 days prior to administration of the study vaccine\n\n          -  Subjects who received another experimental drug or vaccine within 28 days before\n             administration of the study vaccine or are planning to receive another experimental\n             drug or vaccine during the study.\n\n          -  Subjects who had previously received immunoglobulin or blood-derived products within\n             the last 3 months prior to administration of the study vaccine, or are expecting to\n             be treated with immunoglobulin or blood-derived products during the study\n\n          -  Subjects who had received, or are scheduled to receive, systemic immunosuppressive\n             therapy, radiation therapy or high-dose steroid therapy within the last 6 months\n             prior to administration of the study\n\n          -  Subjects who had received, or are expected to receive, the medications listed below:\n             Within 28 days prior to administration of the study vaccine: Oriental herbal\n             medicine, Within 14 days prior to administration of the study vaccine: Prescription\n             drugs, Within 7 days prior to administration of the study vaccine: Over-the-counter\n             medicine (including vitamin/mineral supplements)\n\n          -  Subjects with a history of, or suspected, drug abuse (amphetamine, barbiturates,\n             opioids, benzodiazepines, etc.) based on subject interview and physical examination.\n\n          -  Subjects with excessive consumption of caffeine (> 5 cups/day) and alcohol (>3\n             units/day, 1unit= 10g or 12.5ml of pure alcohol), and excessive smoking (>10\n             cigarettes/day)\n\n          -  Subject with a known allergy to eggs, chicken, or any components of the study vaccine\n\n          -  Subjects who in the investigator's opinion, may not be suitable for vaccination or\n             who may interfere with the objective assessment of the study outcomes."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02111070", 
            "org_study_id": "IY_IFEZ_101"
        }, 
        "intervention": {
            "arm_group_label": "ILYANG Inactivated split influenza vaccine", 
            "description": "0.5mL", 
            "intervention_name": "IL-YANG FLU Vaccine", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Influenza", 
            "Influenza vaccine", 
            "Split influenza vaccine"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul St. Mary's Hospital,The Catholic University of Korea"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open-label, Phase I Clinical Trial to Assess the Immunogenicity and Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects", 
        "overall_official": {
            "affiliation": "IL-YANG Pharmaceutical Co.,LTD", 
            "last_name": "IL-YANG PHARM", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Solicited local reaction: pain, tenderness, redness, swelling Solicited general reactions: fever, nausea/vomiting, diarrhea, headache, fatigue, myalgia", 
                "measure": "Solicited local & general AE, Unsolicited AE", 
                "safety_issue": "No", 
                "time_frame": "up to Day28(+7)"
            }, 
            {
                "description": "Seroprotection: HI antibody titer \u2265 1:40 28 days after the administration of the study vaccine", 
                "measure": "Percentage of subjects achieving seroprotection for HI antibody after administration of the study vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day28(+7)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02111070"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "GMT(Geometric Mean Titer) and GMR(Geometric Mean Ratio), as measured by pre-vaccination (Day 0) HI antibody titer and post-vaccination (vaccination + 28 days) HI antibody titer", 
                "measure": "GMT of HI antibody titer before vaccination and after vaccination", 
                "safety_issue": "No", 
                "time_frame": "Day28(+7)"
            }, 
            {
                "measure": "Percentage of subjects with a pre-vaccination (Day 0) HI antibody titer < 1:40, and a minimum four-fold rise in post-vaccination (vaccination + 28 days) HI antibody titer", 
                "safety_issue": "No", 
                "time_frame": "Day28(+7)"
            }, 
            {
                "measure": "Vital signs measurements, physical examination findings, ECG results, and laboratory measurements (hematology, biochemistry and urinalysis)", 
                "safety_issue": "No", 
                "time_frame": "Day28(+7)"
            }
        ], 
        "source": "Il-Yang Pharm. Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Il-Yang Pharm. Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}